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The incidence of human papillomavirus (HPV)-associated cancer is increasing and HPV
is now implicated in the aetiology of more than 60% of all oropharyngeal squamous
cell carcinomas (OPSCC). In OPSCC, innate immune cells such as neutrophils and
macrophages generally correlate with poor prognosis, whilst adaptive immune cells, such
as lymphocytes, tend to correlate with improved prognosis. This may, in part, be due to
differences in the immune response within the tumour microenvironment leading to the
recruitment of specific tumour-associated leukocyte sub-populations. In this study, we
aimed to examine if differences exist in the levels of infiltrated leukocyte sub-populations,
with particular emphasis on tumour-associated neutrophils (TAN), and to determine
the mechanism of chemokine-induced leukocyte recruitment in HPV-positive compared
to HPV-negative OPSCC. Immunohistochemical analysis showed that HPV-negative
OPSCC contained significantly more neutrophils than HPV-positive tumours, whilst
levels of CD68+ macrophages and CD3+ lymphocytes were similar. Using a 3D
tissue culture model to represent tumour-stromal interactions, we demonstrated that
HPV-negative tumour-stromal co-cultures expressed significantly higher levels of CXCL8,
leading to increased neutrophil recruitment compared to their HPV-positive counterparts.
HPV-negative OPSCC cells have previously been shown to express higher levels of IL-1
than their HPV-positive counterparts, indicating that this cytokine may be responsible
for driving increased chemokine production in the HPV-negative 3D model. Inhibition
of IL-1R in the tumour-stromal models using the receptor-specific antagonist, anakinra,
dramatically reduced chemokine secretion and significantly impaired neutrophil and
monocyte recruitment, suggesting that this tumour-stromal response is mediated by
the IL-1/IL-1R axis. Here, we identify a mechanism by which HPV-negative OPSCC
may recruit more TAN than HPV-positive OPSCC. Since TAN are associated with
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poor prognosis in OPSCC, our study identifies potential therapeutic targets aimed at
redressing the chemokine imbalance to reduce innate immune cell infiltration with the
aim of improving patient outcome.
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INTRODUCTION
The worldwide increasing incidence of human papillomavirus
(HPV)-driven oropharyngeal squamous cell cancer (OPSCC) has
raised the profile of these tumours and intensified interest in this
area of cancer research [1]. Of particular interest is the finding
that HPV-positive OPSCC generally display improved prognosis
and response to therapy than their HPV-negative counterparts,
whose aetiology is generally linked to DNA damage by classical
risk factors such as tobacco use and alcohol consumption rather
than viral infection [2]. In addition to aetiology, the tumour
microenvironment also has a profound influence on tumour
progression. The tumour microenvironment consists of dynamic
molecular interactions between cancer cells, fibroblasts, the
extracellular matrix and immune cell populations, where pro-
tumour factors outweigh those intended to inhibit disease.
In many malignant tumours, a pro-inflammatory tumour
microenvironment drives the recruitment of tumour-infiltrating
leukocytes that in turn have a major effect on tumour progression
[3]. The presence of increased tumour-associated neutrophils
(TAN) and tumour-associated macrophages (TAM) have been
correlated with poor clinical outcome inmany tumours, whilst on
many occasions tumour-infiltrating lymphocytes (TIL) have been
associated with improved prognosis [4]. There is good evidence
to suggest that HPV-positive OPSCC contain abundant CD8+
T-cells that can recognise tumour cell-expressed HPV antigens,
enabling activation of adaptive immune responses to eliminate
cancer cells and impart improved outcome [5–7]. Although
increased levels of TAM and TAN correlate with poor prognosis
in oral squamous cell carcinoma (OSCC) [8, 9], the levels of TAM
in HPV-positive/negative OPSCC are less well-characterised and
to date there are no published studies correlating abundance of
TAN in OPSCC with HPV status.
It has been known for many years that the increased gene
expression and subsequent secretion of chemokines by cells at
infected or inflammatory sites is mediated by pro-inflammatory
cytokines, such as IL-1, that are present within the local
environment [10]. There are 47 different human chemokines
each with specific or overlapping affinities for different leukocyte
populations [11]. Leukocytes are recruited to inflammatory sites
and tumours from the circulation via chemotactic gradients of
chemokines. Although OPSCC cells are known to over-express
a number of chemokines, many now believe that the pro-
inflammatory paracrine signalling between tumour cells and
the surrounding tumour-associated fibroblasts is the driving
force behind elevated chemokine expression in the tumour
microenvironment [12]. The specific type and proportions of
leukocytes recruited to tumours are directly related to the profile
of chemokines released. We have recently demonstrated that
HPV-negative OPSCC cells stimulate tonsillar fibroblasts to
secrete a distinct chemokine-rich profile compared to HPV-
positive OPSCC cells. Moreover, this effect is mediated by the
actions of tumour cell-secreted IL-1 on the IL-1R expressed
by tonsillar fibroblasts [13]. It is therefore plausible that the
chemotactic cues driven by the tumour microenvironment in
HPV-negative OPSCC is different from those in HPV-positive
OPSCC and this may directly account for any differences
observed in tumour-associated leukocyte sub-populations. Here
we examine the abundance of leukocyte populations in HPV-
positive and HPV-negative OPSCC and show for the first
time that TAN are preferentially recruited to HPV-negative
OPSCC. Moreover, using a 3D culture system consisting of
HPV-negative or HPV-positive OPSCC spheroids embedded
in a tonsillar fibroblast-populated stromal matrix to mimic
the tumour microenvironment, we show that both chemokine
secretion and neutrophil recruitment are dependent on IL-1β/IL-
1R paracrine signalling. Our data point to possible intervention
strategies to inhibit TAN recruitment to tumours that may be
beneficial for patient prognosis.
MATERIALS AND METHODS
Human Samples
This study utilised patient samples and associated clinical
data within the period of primary diagnosis 2002–2012.
Patients were selected using the Chemocare database system
(National Health Service, UK) and further cross-referenced
against the histopathological database held at Sheffield Teaching
Hospitals NHS Trust, UK in order to confirm diagnosis
and to identify each tissue biopsy reference number. Patients
were included in the study if there was sufficient tissue
remaining after clinical histopathological diagnosis for TMA
generation and if there was a reasonably complete dataset of
associated clinicopathological information. All biopsy material
was obtained before commencement of anti-cancer treatment.
Paraffin-wax embedded tissue samples were retrieved and
collated in a blinded fashion with respect to HPV status.
HPV positivity using RNAScope R© was determined as described
in Hendawi et al. [14], whilst expression of p16 staining
was assessed using the H-score system with a 300-point
cut-off for positivity [14, 15]. Overall HPV status in the
samples was found to be proportionate to the UK prevalence
of HPV OPSCC, reflecting that a representative population
sample was used in this study. Clinical data regarding tumour
recurrence, clinical status and follow-up were retrieved from the
patient’s medical files at the Sheffield Teaching Hospital NHS
Foundation Trust, UK. Overall survival was determined by the
difference between the date of treatment and either the date
of death due to the tumour or last follow-up. The study was
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Tissue microarrays (TMA) were constructed by selecting
tumour regions displaying more than 70% cellularity with
minimal necrosis and marked on haematoxylin and eosin-
stained sections. TMA were constructed using a tissue
arrayer with 3 × 1.0mm diameter cores from each tissue
block arranged at mapped locations into recipient paraffin
blocks. TMA were sectioned (5µm) by microtome onto
SuperfrostTM adhesive glass slides (ThermoFisher Scientific) and
automated immunohistochemical staining performed for CD3
(T lymphocytes, Agilent, clone F7.2.38), CD68 (macrophages,
Agilent, clone KP-1) and myeloperoxidase (MPO, Agilent,
code IS511,) by the Histology Department, Sheffield Teaching
Hospitals NHS Foundation Trust. Stained TMA sections were
imaged using an Aperio ScanScope CS slide scanner (Aperio
Technologies, Vista, USA). Digital analysis was performed
using QuPath software (https://qupath.github.io) [16]. Further
details of the QuPath analytical approach is provided in
Supplementary Figure 1. Cores with insufficient histology
(<80% area) were not included in QuPath analysis. Each OPSCC
case was represented by at least two cores in QuPath analysis
and the image analysis data was calculated as the mean percent
number of positively stained cells as a proportion of the total
number of cells in each core. Leukocytes within blood vessels
were excluded from the analysis.
Cell Culture
The OPSCC HPV-positive cell line UPCI-SCC90 was provided
by Prof. Susanne Gollin, University of Pittsburgh and the HPV-
negative cell line FaDu was purchased from the American Type
Culture Collection. The authenticity of cell lines was verified by
short tandem repeat analysis and their HPV status confirmed
by the HPV Cytology Screening Unit using the cobas R© qPCR
HPV testing kit that detects a 200 bp region within the L1
region of the HPV genome (Sheffield Teaching Hospital NHS
Foundation Trust, UK). Normal tonsillar fibroblasts (NTF)
were isolated from biopsies obtained from tonsillectomies at
the Sheffield Teaching Hospitals NHS Foundation Trust with
written, informed consent (ethical approval 09/H1308/66) as
described previously [17]. For this study, NTF isolated from one
donor was used in all experiments to limit experimental variation.
UPCI-SCC90 cells and NTF were cultured in Dulbecco’s
Modified Eagle’s Medium and FaDu in RPMI-1640, both media
were supplemented with 10% v/v foetal calf serum (FCS), 2mM
L-glutamine, 100 IU penicillin and 100µg/ml streptomycin,
(all medium and supplements from Sigma-Aldrich) and cells
cultured in a humidified incubator with 5% CO2 at 37
◦C. All cells
were confirmed mycoplasma-free before use in experiments.
Leukocyte Isolation
Human peripheral blood leukocytes were isolated from the
venous blood of healthy donors with written, and informed
consent (University of Sheffield ethical approval, 012597) as
previously described [18]. The donors were two male and
one female, none had received the HPV vaccine, none were
taking prescription medication or had been ill in the previous
2 weeks, and all were non-smokers. Blood was anti-coagulated
using sterile 3.8% sodium citrate (Sigma-Aldrich, W302600) and
centrifuged at 400 g for 20min to separate the plasma from
leukocytes. Mononuclear cells were isolated by Ficoll-Paque Plus
(GE Healthcare, GE17-1440-02) density-gradient centrifugation,
washed twice with Hank’s balanced salt solution (HBSS,
ThermoFisher Scientific, 14170112) and erythrocytes removed
from neutrophils by hypotonic lysis. Total neutrophils and
mononuclear cells were re-combined by re-suspension in RPMI-
1640 supplemented with 10% v/v FCS and 2mM L-glutamine
then labelled with CellTrackerTM Deep Red dye (ThermoFisher
Scientific, C34565) according to the manufacturer’s instructions.
Cell viability was assessed by trypan blue (Sigma-Aldrich, T8154)
exclusion and was >95% by light microscopy.
3D Tumour—Stromal in vitro Culture
Models
Multicellular tumour spheroids (MCTS) were generated as
previously described [19]. Briefly, 100 µL of a 1 × 105 cells/mL
suspension of either FaDu or UPCI-SCC90 cells were added to
each well of a 96-well plate previously coated with 100 µL sterile
1.5% w/v type IV agarose (Sigma-Aldrich, 121852) in serum-free
medium. Culture plates were incubated for 2 d in a humidified
incubator with 5% CO2 at 37
◦C to allow MCTS formation.
To prepare 3D tumour-stromal in vitro models, type 1 rat-tail
collagen (produced in-house) was mixed with 10 × RPMI-1640,
10% FCS, 2mM L-glutamine and reconstitution buffer (2.2%
NaHCO3, 4.8% HEPES, 0.25% NaOH in dH2O, all from Sigma-
Aldrich) and pH adjusted to 7.4. One millilitre collagen was
added to 2 × 105NTF and 60 FaDu or UPCI-SCC90 MCTS,
the contents mixed to evenly disperse the NTF/spheroids and
the hydrogel allowed to solidify for 1 h at 37◦C, 5% CO2 in a
24-well plate. A ratio of ∼1:3 NTF to tumour cells was used
in accordance with our previous 2D work [13]. Once set, 1mL
of serum-containing medium was added and models incubated
for a further 24 h. Models were then washed twice with serum-
free medium and incubated in the absence or presence of 1
or 10µg/ml anakinra (Trade name Kineret, Amgen) in 500 µl
serum-free medium and further incubated for 24 h. Levels of
anakinra were maintained throughout the experiment. Culture
medium was then removed and stored at −20◦C for further
analysis by ELISA.
To generate immune cell-containing 3D tumour-stromal
models, 200 µL of CellTrackerTM-labelled total leukocytes were
added to the surface of either FaDu or UPCI-SCC90 3D co-
culture models in the absence or presence of 10µg/ml anakinra,
and incubated for 24 h. Models were washed twice with HBSS
to remove non-infiltrating leukocytes then total cells dispersed
from the models using type I collagenase (2 mg/mL in HBSS,
Sigma-Aldrich, SCR103), washed in HBSS, sieved to remove
cell aggregates and then fixed with 2% paraformaldehyde.
Flow cytometry (FACSCaliburTM with associated CellQuestTM
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TABLE 1 | Oropharyngeal squamous cell carcinoma patient demographics and clinical characteristics.
Characteristics (%) HPV-positive (%) HPV-negative (%) P
Total Subjects 59 (100) 40 (68) 19 (32)
Sex Female 14 (24) 10 (25) 4 (21) 0.739
Male 45 (76) 30 (75) 15 (79)
Age (year) Median 57 56 0.651
Range 29-68 31-70
Alcohola Never 3 (7.5) 0 (0) 0.018







Smokingb Smoker 13 (32.5) 9 (47) 0.032







Site Tonsil 28 (70) 9 (47) 0.205
Base of tongue 11 (27.5) 7 (37)
Post wall of pharynx 0 (0) 1 (5)
Soft palate 0 (0) 1 (5)
Oropharynx (not otherwise specified) 1 (2.5) 1 (5)
Disease stage Stage I 8 (20) 2 (11) 0.271
Stage II 16 (40) 5 (26)














N-stagec N0 3 (7.5) 3 (15.7) 0.654







M-Stagec 0 (0) 0 (0)
Gradec Poor 25 (62.5) 9 (48) 0.339














aModerate alcohol consumption is defined as up to 10–25 units/week, heavy consumption is defined as >25 units/week.
bEx-smoker is defined as an individual who has smoked at least 100 cigarettes in their lifetime but who had quit smoking within the last 12 months.
cBrierly et al. [20].
Two-sided Chi-squared or Fisher’s exact-test was used for comparison of categorical variables and two-tailed Student t-test was used for continuous variables. P < 0.05 are given in
bold text.
software, BD Biosciences) was used to plot side scatter against
fluorescence (650 nm emission) to determine the total number of
infiltrating leukocytes into tumour-stromal models. These cells
were further gated and side scatter plotted against forward scatter
to determine the relative numbers of neutrophils, monocytes
and lymphocytes according to their cell size and granularity (see
Figure 5 for gating strategy). Each experiment was performed
using the leukocytes isolated from one donor with each test
performed in technical triplicates and the entire experiment
was repeated three times (n = 3) using the blood from a
different donor (two male, one female, all non-HPV-vaccinated
and non-smokers) on each occasion.
Cell Viability
Cell viability as measured by metabolism of PrestoBlueTM
(ThermoFisher Scientific, P50200) was performed according
to the manufacturer’s instructions. 3D models were incubated
with serum-containing medium for 48 h at 37◦C, 5% CO2.
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Models were washed with HBSS before addition of fresh medium
containing PrestoBlueTM (1:10 v/v) and then incubated for
a further 2 h. Medium was removed and the colour change
measured by fluorescence excitation at 560 nm and emission at
590 nm.
Chemokine Level Quantification
Conditioned medium collected from 3D models in the
absence or presence of anakinra was subjected to ELISA
for CXCL8, CCL2 (BD Biosciences 555244 and 559017,
respectively) and CCL5 (R&D systems, DRN00B) according to
the manufacturer’s instructions.
Statistics
All data are expressed as mean± SD of at least three independent
experiments performed in triplicate unless otherwise stated.
Statistical analysis was undertaken usingGraphPad Prism (v8.4.3,
GraphPad Software, San Diego, CA). For demographic and
clinical data two-sided Chi-squared or Fisher’s exact-test was
used for comparison of categorical variables and two-tailed
Student t-test was used for continuous variables. For TMA
data pairwise comparisons were performed usingMann-Whitney
U-test, and for ELISA data group-wise comparisons were made
using one-way ANOVA with Tukey’s multiple comparisons test.
Flow cytometric data was analysed using one sample t and
Wilcoxon-test. SPSS (v22, IBM Chicago, IL) was used to test for
HPV-status effects in cumulative survival curves according to the
Kaplan-Meier method with comparisons between survival curves
made using the log rank test. Differences between groups was
considered significant when p < 0.05.
RESULTS
HPV-Positive Status Is Associated With
Improved 5-Year Survival in OPSCC
The patient demographic information is summarised in
Supplementary Table 1. The median age was 57 years for
HPV-positive and 56 years for HPV-negative patients. There
was a statistically significant difference in the levels of alcohol
(p = 0.018) and smoking (p = 0.032) between subjects with
HPV-positive and HPV-negative OPSCC. However, there was
no significant difference between any of the clinical parameters
analysed (Table 1). OPSCC cases were stratified for HPV-status
and overall survival over a 5-year follow-up period examined.
Kaplan-Meier survival analysis showed that individuals with
HPV-positive OPSCC correlated significantly (p = 0.04) with
better overall 5-year survival than individuals with HPV-negative
OPSCC (Figure 1).
HPV-Negative OPSCC Contain Elevated
Numbers of Tumour-Associated
Neutrophils Than HPV-Positive OPSCC but
Levels of Other Tumour-Associated
Leukocytes Are Similar
The number of tumour-infiltrating leukocytes present in
HPV-negative or HPV-positive OPSCC was measured by
FIGURE 1 | Individuals with HPV-positive OPSCC display significantly better
overall 5-year survival than those with HPV-negative OPSCC. Kaplan-Meier
analysis followed by log rank-test showed that individuals with HPV-positive
OPSCC (n = 40) correlated with significantly (p = 0.04) improved overall
5-year survival than individuals with HPV-negative OPSCC (n = 19).
immunohistochemical staining of TMA for myeloperoxidase
(MPO; neutrophils), CD68 (macrophages) or CD3 (pan T cells)
followed by QuPath image analysis and the percent number
of positively stained cells as a proportion of the total number
of cells in each core calculated (Supplementary Figure 1).
There was a significant (p = 0.003) increase in the level of
MPO-immunopositive staining in HPV-negative (median
9.04%, n = 19) compared with HPV-positive (median 2.98%,
n = 40) OPSCC, indicating the increased prevalence of
neutrophils in HPV-negative compared to HPV-positive OPSCC
(Figures 2A,B). In contrast, similar levels of macrophages,
identified by CD68-positive staining, were observed in both
HPV-positive (median 5.49%, n = 39) and HPV-negative
(median 2.64%; p = 0.277) OPSCC (Figures 2C,D). Likewise,
the levels of T lymphocytes were similar in both HPV-positive
(median 4.13%, n = 38) and HPV-negative (median 2.14%,
n= 17; p= 0.333) OPSCC (Figures 2E,F). The tissue neutrophil
to lymphocyte ratio (NLR) for HPV-negative OPSCC was
significantly greater (median 2.60) than the ratio for HPV-
positive tumours (median 0.773; p < 0.01). There were no
significant differences observed in the levels of infiltrating
leukocyte populations between HPV-positive and HPV-negative
OPSCC at disease stage (Supplementary Figure 2) or T-stage
(Supplementary Figure 3) examined. Taken together, these
data show that HPV-negative OPSCC contained significantly
more TAN compared to HPV-positive OPSCC whereas
levels of CD68 and CD3-positive leukocyte populations
were similar.
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FIGURE 2 | HPV-negative OPSCC contain more neutrophils than HPV-positive OPSCC. Levels of tumour associated-leukocyte populations for HPV-positive and
HPV-negative OPSCC tissue sections were analysed by QuPath. (A,B) MPO+ neutrophils, (C,D) CD68+ macrophages, (E,F) CD3+ T lymphocytes. Scale
bar = 250µm for whole cores (left), and 50µm for magnified core images (centre) and corresponding QuPath image analysis (right). Brown staining shows
immuno-positively identified cells within the cores. Data are presented as the median and interquartile range of percent positively stained cells as a proportion of the
total number of cells. Differences between groups was determined using a non-parametric Mann-Whitney U-test; **p < 0.01.
HPV-Negative 3D Tumour-Stromal Culture
Models Produce Significantly Higher
Levels of Chemokines than their
HPV-Positive Counterparts
Our previously published data using a 2D monolayer
experimental culture system showed that when cultured
with conditioned medium derived from several different
HPV-negative OPSCC tumour cells, NTF are stimulated to
secrete high levels of chemokines in an IL-1-dependent manner
[13]. Here we used a 3D in vitro construct containing HPV-
negative (FaDu) or HPV-positive (UPCI-SCC90) multi-cellular
tumour spheroids (MCTS) (Supplementary Figures 4A–F)
embedded in a NTF-populated stromal collagen matrix
in an attempt to more accurately model the intimate cell-
cell OPSCC tumour-stromal cell interactions within a 3D
environment, similar to those occurring in vivo. Haematoxylin
and eosin stained sections of the tumour-stromal 3D model
demonstrated an evenly distributed fibroblast-populated
matrix containing MCTS that often display a central
necrotic core surrounded by several layers of tumour
epithelium (Supplementary Figures 4E,F). The histological
appearance of the tumour-stromal 3D model is comparable
to that frequently observed with OPSCC tumours in vivo
(Supplementary Figure 4G) although the density of the
fibroblasts within the in vitro models appears to be lower than
observed in vivo.
Cell viability within collagen gels was measured for NTF,
FaDu or UPCI-SCC90 spheroids alone or in combination.
The mean fluorescence readings for all tests containing cells
were increased compared to collagen alone showing that
cells remained metabolically active and therefore viable whilst
embedded in collagen.When in co-culture with NTF, both UPCI-
SCC90 and FaDu displayed an additive and significant (p < 0.05)
increase in fluorescence compared to when the spheroids or
NTF were cultured alone, reflecting the synergistic nature of the
co-culture system (Supplementary Figure 4H).
We nextmeasured the levels of chemokines released inmodels
containing NTF or MCTS alone or when in combination. We
chose to measure CXCL8, CCL2 and CCL5, as these chemokines
are well-recognised, potent chemoattractants for neutrophils,
monocytes and lymphocyte populations, respectively. When
cultured alone, NTF produced low levels for all three of the
chemokines tested with 0.12 ± 0.007 ng/ml, 0.20 ± 0.02 ng/ml
and 0.06± 0.005 ng/ml for CXCL8, CCL2 and CCL5, respectively
(Figures 3A–C). This was also the case for UPCI-SCC90 MCTS
when cultured alone (CXCL8−0.09 ± 0.01 ng/ml, CCL2−0.14
± 0.02 ng/nl and CCL5−0.13 ± 0.001 ± ng/ml; Figures 3A–C).
Chemokine secretion was not significantly increased when NTF
were co-cultured with UPCI-SCC90 MCTS (CXCL8−3.52 ±
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FIGURE 3 | FaDu HPV-negative OPSCC 3D tumour-stromal models display
increased chemokine secretion compared to their UPCI-SCC90 HPV-positive
(Continued)
FIGURE 3 | counterparts. Chemokine secretion of NTF-populated collagen
alone, UPCI-SCC90 and FaDu MCTS alone or NTF/MCTS co-cultures for (A)
CXCL8, (B) CCL2, and (C) CCL5. Data are mean ± SD for at least 5
independent experiments. Statistics were performed using One-way ANOVA
with Tukey’s multiple comparisons test. **p < 0.01, ***p < 0.001.
FIGURE 4 | Chemokine secretion by HPV-negative OPSCC 3D
tumour-stromal models is reduced by anakinra. (A) CXCL8, (B) CCL2, and
(C) CCL5 secretion from HPV-positive UPCI-SCC90/NTF or HPV-negative
FaDu/NTF co-cultures in the absence or presence of 1µg/mL (A–C)
or 10µg/mL (D–F) anakinra. Data are mean ± SD for at least 4 independent
experiments. Statistics were performed using Mann Whitney U-test.
*p < 0.05, **p < 0.01, ***p < 0.001.
1.38 ng/ml, CCL2−0.28± 0.04 ng/nl and CCL5−0.14± 0.004±
ng/ml; Figures 3A–C). In contrast, for CXCL8 (5.28± 0.6 ng/ml;
p < 0.05) and CCL2 (1.15± 0.09 ng/ml; p < 0.001), FaDu MCTS
alone secreted significantly more chemokine than NTF or UPCI-
SCC90MCTS alone, and for CCL5 (2.38± 0.23 ng/ml; p< 0.001)
significantly more than NTF/UPCI-SCC90 co-culture models
(Figures 3A–C). However, when FaDu MCTS were combined
with NTF in a 3D tumour-stromal model, levels of CXCL8
increased 7-fold (39.1 ± 4.34 ng/ml; p < 0.001) and CCL2 by
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3-fold (3.93 ± 0.69 ng/ml; p < 0.001, Figures 3A,B), showing
that NTF and FaDu act synergistically in stimulating production
of these chemokines. Levels of CCL5 also increased in the 3D
tumour-stromal model compared to MCTS alone, although the
difference between the amounts of chemokine released was much
less [2.4 ± 0.2 ng/ml compared to 3.3 ± 0.3 ng/ml for FaDu
MCTS alone and NTF + FaDu MCTS, respectively (p < 0.01);
Figure 3C]. These data indicate that OPSCC cells within a 3D
environment interact with NTF via paracrine signalling.
Synergistic Production of Chemokines by
HPV-Negative 3D Tumour-Stromal Culture
Models Is Mediated by IL-1/IL-1R
We next tested if the IL-1/IL-1R axis was the main paracrine
signalling pathway in mediating elevated chemokine release by
inhibiting this pathway using anakinra, a highly specific IL-1R
antagonist. Here, 3D models containing either UPCI-SCC90 or
FaDu MCTS co-cultured with NTF were pre-incubated with 1
or 10µg/ml anakinra and levels of CXCL8, CCL2 and CCL5
measured in the conditioned medium after 24 h. Pre-incubation
with 1µg/ml anakinra dramatically reduced the production
of CXCL8 and CCL2 but not CCL5 for both UPCI-SCC90
and FaDu 3D tumour-stromal models. Specifically, in FaDu-
stromal 3D experimental models, CXCL8 was reduced 18-fold
(p < 0.001) and CCL2 6-fold (p < 0.01) upon treatment with
anakinra, whereas CCL5 levels remained the same as untreated
models (Figures 4A–C). Inhibition of chemokine secretion was
even more pronounced when models were pre-incubated with
10µg/ml anakinra, where levels of CXCL8, CCL2 and CCL5
were almost abolished in anakinra-treated FaDu stromal models
(p < 0.01; Figures 4D–F).
HPV-Positive UPCI-SCC90 Tumour-Stromal
Models Recruit Fewer Neutrophils than
their HPV-Negative FaDu Counterparts
Reproducing What Is Observed in vivo
Fluorescently labelled leukocytes isolated from whole blood
were added to HPV-positive UPCI-SCC90 or HPV-negative
FaDu tumour stromal models and the levels of total infiltrating
leukocytes, as well as individual leukocyte subsets, quantified by
flow cytometry using a gating strategy to identify neutrophils,
monocytes and lymphocytes based on their well-characterised
forward and side scatter profiles (Figures 5A–D). There were
36.8 ± 14.9% fewer total leukocytes infiltrating into HPV-
positive UPCI-SCC90 tumour-stromal models compared to
those infiltrating into the HPV-negative FaDu tumour-stromal
models (p= 0.05; Figure 5E, data showing the actual numbers of
total leukocytes or leukocyte subsets infiltrating into the tumour-
stromal models for each individual experiment is provided in
Supplementary Table 1). When broken down into leukocyte
subsets, the proportion of neutrophils infiltrating into HPV-
positive UPCI-SCC90 tumour-stromal models was 52.3 ±
19.9% less (p = 0.045) when compared to those infiltrating
HPV-negative FaDu tumour-stromal models, whereas, although
overall decreased, the proportion of infiltrating monocytes
(28.8 ± 27.9%) and lymphocytes (19.8 ± 15.5%) were
not statistically different between UPCI-SCC90 and FaDu
models (Figures 5B,C,E). Although these flow cytometric results
have a relatively large standard deviation due to donor-
to-donor variability, the data reflect those observed in the
immunohistochemical analysis of leukocyte infiltration in the
patient OPSCC tumour sections, where greater levels of
tumour-associated neutrophils were observed in HPV-negative
compared to HPV-positive tumours. Since pre-treatment with
anakinra significantly reduced the levels of chemokines (CXCL8
and CCL2) in both FaDu and UPCI-SCC90 tumour-stromal
models (Figure 4), we reasoned that these anakinra-treated
tumour-stromal models would therefore also recruit fewer
leukocytes. This was indeed the case with anakinra treatment
reducing the numbers of infiltrating leukocytes for both
UPCI-SCC90 and more dramatically for FaDu tumour-stromal
models (Supplementary Figure 4). Here, anakinra-treated FaDu
tumour-stromal models recruited 45.2 ± 12.0% (p = 0.023)
fewer total leukocytes than untreated models (Figures 5B,D,F).
At the leukocyte subpopulation level, the proportion of
neutrophils and monocytes infiltrating FaDu tumour-stromal
models was significantly reduced by 45.9 ± 12.3% (p = 0.023)
and 52.9 ± 16.4% (p = 0.030) respectively, upon anakinra
treatment, whereas the proportion of lymphocytes infiltrating
into anakinra-treated FaDu tumour-stromal models was not
significantly different (40.3 ± 17.5%; p = 0.057) from untreated
models (Figure 5F).
DISCUSSION
The tumour microenvironment plays a major role in directing
the course of tumour progression, and factors that regulate
the immune response and direct the infiltration of tumour-
associated leukocytes are key to this process [21]. It is
important to understand the overall tumour-associated immune
burden and mechanisms of how this is controlled because
several lines of evidence show that the abundance of certain
leukocyte subsets within tumours correlate with either poor or
improved prognosis.
Although our patient cohort was relatively small, HPV
status still stratified the patient groups in terms of outcome,
where patients with HPV-positive OPSCC displayed significantly
improved 5-year survival than those with HPV-negative
tumours, as observed in several other studies [2, 6, 22, 23]. The
percent 5-year overall survival for HPV-positive patients seen
in this study is similar to those observed in previous studies,
whereas we observed an increased 5-year overall survival for
HPV-negative OPSCC subjects compared to previous studies
[2, 6, 22, 23]. This is likely due to the relatively small sample
size for the HPV-negative cohort used in this study compared
to other larger studies as well as differences in local detection
and/or treatment regimens. Upon leukocyte tumour burden
assessment, we found TAN to be significantly more abundant
in HPV-negative than HPV-positive tumours; the first time
that differences in TAN levels in OPSCC has been shown
to correlate with HPV status. We used a validated antiserum
specifically raised against neutrophil MPO to detect the presence
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FIGURE 5 | Anakinra reduces leukocyte recruitment in an in vitro 3D model of OPSCC. Infiltration of leukocytes into 3D OPSCC tumour-stromal models in the
absence or presence of 10µg/ml anakinra. (A) Fluorescence-based gating strategy to identify leukocyte population (red) compared to tumour (orange) or NTF (blue)
cell populations. Total leukocytes identified in panel A were re-gated for their well-characterised side and forward scatter properties to determine the number of
neutrophils (N), monocytes (M) and lymphocyte (L) populations infiltrating into (B) FaDu tumour-stromal models and (C) UPCI-SCC90 tumour-stromal models in the
absence of anakinra, or (D) FaDu tumour-stromal models pre-treated with 10µg/ml anakinra for 24 h before addition of leukocytes. (E) Percent reduction in the
number of leukocytes infiltrating HPV-positive UPCI-SCC90 tumour-stromal models relative to those infiltrating HPV-positive FaDu tumour-stromal models. (F) Percent
reduction in the number of leukocytes infiltrating anakinra treated (10µg/ml) HPV-negative FaDu tumour-stromal models compared to untreated FaDu tumour-stromal
model controls. Data in E and F are mean ± SD for 3 independent experiments with each experiment being performed using the blood from an individual donor.
Statistics were performed using one sample t and Wilcoxon-test. *p < 0.05.
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of TAN, a biomarker commonly used by diagnostic pathology
laboratories for the detection of neutrophils. MPO may not be
as specific as less commonly used markers such as CD15 and
CD66b, although these biomarkers too are expressed by other
granulocytes. Unfortunately, we were unable to correlate TAN
levels with prognosis for HPV status cases due to the sample
size. However, similar data have been reported for OSCC [24],
although this form of cancer rarely harbours oncogenic HPV
[25]. Here, Li et al., observed increased abundance of CD15+
neutrophils in HPV-negative compared to HPV-positive OSCC,
as well as finding that high levels of neutrophils correlated with
poor 5-year survival, increased lymph node metastasis and were
an independent prognostic factor for OSCC [24]. Using The
Cancer Genome Atlas (TCGA) data set Chen et al., also found
a higher neutrophil genetic imprint for HPV-negative compared
to HPV-positive head and neck cancer [26].
In other tumour types, high levels of TAN have been shown
to drive tumour progression by producing factors such as
reactive oxygen species that initiate further DNA mutations
[27], and by secreting potent pro-tumour factors such as
vascular endothelial growth factor andmatrix metalloproteinases
that promote tumour angiogenesis [28, 29], and transforming
growth factor beta (TGF-β) that induces myofibroblast formation
[30]. Moreover, neutrophils that display an immunosuppressive
phenotype upon stimulation by tumour micro-environmental
cues [so called polymorphonuclear myeloid-derived suppressor
cells (PMN-MDSC)] have been shown to accumulate in both
patient biopsies and murine experimental models of head
and neck squamous carcinoma (HNSCC), where they inhibit
the tumouricidal functions of natural killer cells by secretion
of TGF-β, nitric oxide and arginase-1 [31, 32]. Given these
findings, it could be speculated that high TAN levels and
their associated secreted factors are key in driving tumour
immunosuppression, progression, metastasis and therefore poor
outcome in HPV-negative OPSCC. Investigation of the TAN
phenotypes in HPV-negative and HPV-positive OPSCC in future
studies is warranted.
Similar to TAN, increased levels of TAM have been shown
to correlate with poor prognosis in several tumours including
HPV-negative OSCC [9, 33]. Although we observed high levels
of TAM in tumours there was no significant difference in their
abundance between HPV-positive and HPV-negative OPSCC.
Our data is in line with other studies reporting similarities in
overall TAM levels and HPV status in OPSCC and HNSCC [7,
26, 34]. In contrast, Seminerio et al., found increased prevalence
of CD68+ macrophages in HPV-positive compared to HPV-
negative OPSCC in the intra-epithelial but not stromal tumour
component [33]. It is possible that different TAM phenotypes
are recruited to OPSCC. Although we did not examine TAM
polarisation status, a recent study found a higher M1/M2
TAM ratio in HPV-positive HNSCC that may account for
differences [26].
Much attention has been recently paid to TIL that are
correlated with improved prognosis in many tumours [35] and
are the basis for several current immunotherapy approaches
that have had variable success in treating head and neck
cancers [36]. Using CD3, a pan T cell marker, we found no
difference in the levels of CD3+ lymphocytes in HPV-positive
compared to HPV-negative OPSCC in our patient cohort, a
similar finding previously observed by others [34, 37]. However,
there is now compelling evidence that it is the recruitment
of specific lymphocyte subsets that are crucial in driving anti-
tumour responses, in particular CD8+T cells, where the ability to
control HPV-positive tumours is likelymediated by CD8+T cell-
specific recognition of HPV-derived antigens [38, 39]. Indeed,
numerous reports have shown increased abundance of CD8+ T
cells in HPV-positive compared to HPV-negative OPSCC where
their presence is correlated with overall improved survival [5–
7, 37, 40, 41]. In addition, CD20+ B cells [34, 40, 42] and
FoxP3+Treg [5, 34] are also increased inHPV-positive compared
to HPV-negative OPSCC, suggesting a complex interplay in
adaptive immunity in response to HPV-driven oncogenesis. In
light of this substantial evidence we did not pursue further
lymphocyte characterisation at the sub-population level.
The ratio of circulating peripheral blood neutrophils in
relation to lymphocytes has been suggested as a potential
prognostic marker for many cancers including OPSCC [43, 44].
A high circulating neutrophil to lymphocyte ratio (NLR) has
been found for both HPV-positive and HPV-negative OPSCC
[45]. In HPV-positive OPSCC, a high NLR was associated with
higher T classification, lower 5-year overall survival and disease-
free survival [46]. Similarly, in a large cohort study, Huang
et al. found higher levels of circulating neutrophils in HPV-
negative compared to HPV-positive OPSCC, although both
correlated with lower overall survival compared to patients
with lower numbers of circulating neutrophils [47]. Contrary
to this, high circulating lymphocyte levels were associated
with improved recurrence-free survival in HPV-positive OSCC.
However, following multivariate analysis the investigators found
that a high circulating neutrophil count predicted for lower
overall and recurrence-free survival for only the HPV-positive
cohort [47]. In contrast, Rosculet et al. found that NLR was an
indicator for both recurrence-free and overall survival in OPSCC
but this association was lost whenHPV-status was included in the
analysis [48]. In support of this, a high NLR predicted for a worse
5-year overall survival compared to a low NLR in HPV-negative
OPSCC [49]. Moreover, Rachidi et al. found that the circulating
NLR was significantly lower in HPV-positive OPSCC compared
to the HPV-negative counterparts [50].
This study showed that the tissue NLR is significantly
greater for HPV-negative than HPV-positive OPSCC,
which is supportive of some but not all of the current
circulating NLR data. There may be a discourse between
the numbers of circulating leukocytes and those recruited to
the tumour micro-environment particularly for lymphocytes,
as it appears that HPV-positive OPSCC contain greater
numbers of specific subsets (CD8+ T cells, CD20-B cells
and FoxP3+Treg) than their HPV-negative counterparts
that are also associated with overall improved survival
in HPV-positive OPSCC [5–7, 37, 40, 41]. Larger scale
tissue-based immunohistochemical analysis in concert with
measurement of circulating NLR is required to resolve the
suitability of this type of analysis for prognostication of OPSCC
with HPV-status.
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Given the striking increase in TAN numbers in HPV-negative
compared to HPV-positive tumours, we decided to examine
the mechanisms by which the disparity in TAN abundance
may be mediated. Recruitment of leukocytes to tumours is
driven by chemokines; with specific chemokines responsible
for the recruitment of particular leukocyte subsets and several
studies have reported that OPSCC cells express a number
of chemokines [13, 41, 51]. We reasoned that HPV-negative
tumours would produce more neutrophil-specific chemokines
than HPV-positive tumours as a mechanism to recruit increased
numbers of TAN. Indeed, using a rudimentary 2D culture
medium transfer model we previously showed that NTF were
stimulated to secrete elevated levels of several cytokines in
response to the culture medium from a number of HPV-
negative but not HPV-positive OPSCC cell lines [13, 52].
Moreover, this increase was mediated in an IL-1-dependent
manner with IL-1 liberated from HPV-negative OPSCC cell lines
acting on the NTF IL-1R to stimulate chemokine production
[13]. However, traditional 2D-based monolayer cell culture
systems lack the 3D architecture and the spatial complexity
that give solid tumours their characteristic features such as
gradients for oxygen, pH, nutrition and waste products that
give rise to areas of tumour necrosis and hypoxia, and so data
generated in 2D often does not reflect what occurs in 3D. Most
tumours grow as 3D masses closely surrounded by a fibroblast-
populated stroma that communicate with tumour and other cells
via paracrine signalling, driving tumour progression. In vivo
orthotopic tumours cannot be used because the oropharyngeal
cavity of rodents is small and any sizable tumour grown at this
site would cause rapid asphyxiation and so in vivo models of
OPSCC are limited to subcutaneously grown tumours that are
far removed in terms of tissue structure and microenvironment
than the tumours observed in humans. In addition, HPV is
not a natural host of rodents and so an inappropriate immune
response may ensue giving rise to false-positive data. We
therefore endeavoured to recreate the tissue architecture using
tumour spheroids [structures that are known to replicate many
biophysical features of avascular tumours, [53]], embedded in a
NTF-populated collagenmatrix to more closely mimic the in vivo
OPSCC microenvironment.
Using these 3D tumour-stromal models we observed
that HPV-negative FaDu tumour/NTF co-cultures produced
substantially more chemokines than NTF or FaDu MCTS
cultured alone, and importantly, much more than UPCI-
SCC90 HPV-positive tumour-stromal models. Furthermore,
expression of the neutrophil-specific chemokine CXCL8 was
produced at significantly higher levels than CCL2 or CCL5
in HPV-negative tumour-stromal models, suggesting that
neutrophil-specific chemokines may out-weigh those for
monocytes and lymphocytes, potentially skewing leukocyte
subset recruitment in these tumours. We were unable to produce
reliable and consistent MCTS from other HPV-positive cells
lines and so our 3D analysis is limited to FaDu and UPCI-SCC90
cell lines. However, the chemokine profiles detected using these
MCTS directly correlated with the profiles observed for other
HPV-positive/negative cell lines in our previous 2D study [13],
providing some evidence that these phenomena is not cell line
specific but may be a general occurrence for HPV status. In
support of this, analysis of the Gene Expression Omnibus (GEO)
and TCGA databases showed significantly elevated levels of
CXCL8 in HPV-negative compared to HPV-positive tumours
[24], consistent with our in vitro 3D model data. In addition
to CXCL8, increased abundance of other neutrophil-specific
chemokines such as CXCL1, CXCL5 and CXCL6 is likely, as
evidenced by our previous cytokine array analysis [13], and this
may further skew the imbalance in leukocyte recruitment in
favour of preferential neutrophil recruitment.
Blocking IL-1R using the highly specific antagonist anakinra
almost completely abolished chemokine production, providing
further support to the notion that IL-1/IL-1R paracrine
signalling between HPV-negative tumour cells and NTF is
of paramount importance for chemokine production. In
support of this, increased levels of IL-1β have been found
in HPV-negative compared to HPV-positive OPSCC patient
samples [13, 41].
Tonsillar [54] and oral keratinocytes [55] constitutively
express IL-1 at basal levels, but levels significantly increase
upon DNA-induced malignant transformation [56, 57] and
this appears to be important in tumour progression, as
pharmacological inhibition of IL-1β interrupts chemically-
induced oral carcinogenesis in rodent models [57]. HPV
infection appears to ablate the ability of keratinocytes to express
IL-1β; indeed we previously observed low levels of IL-1α and
IL-1β in HPV-positive compared to HPV-negative cell lines
and tumour biopsies [13]. Moreover, a complete lack of IL-1β
gene expression has also been observed in HPV-positive cervical
carcinoma cell lines [56]. In HPV infected cervical keratinocytes,
Niebler et al., demonstrated that IL-1β is continually degraded
in a HPV-16, E6 driven proteasome-dependent process via
ubiquitin ligase, leading to complete loss of the cytokine as
HPV-induced malignancy develops [56]. It is plausible that such
a mechanism also occurs in HPV-positive OPSCC cells. Since
IL-1β is known to drive NF-κB-induced chemokine expression
in many cell types, it is logical that HPV-negative OPSCC
are driven to secrete high levels of chemokines and therefore
recruit increased numbers of TAN, whereas chemokines are
much less abundant in HPV-positive OPSCC and so TAN
recruitment is reduced. Li et al. overexpressed HPV18 E7 in
the HPV-negative adenosquamous OSCC cell line Cal27 and
showed that this directly reduced CXCL8 gene expression and
protein secretion, suggesting that HPV gene products may have
a more direct effect on chemokine production [24], although
such a mechanism has not been shown for OPSCC cells. HPV
infection may act to suppress TAN recruitment to HPV-positive
OPSCC, although more research is required to further define
this link.
Given the high levels of chemokines produced by the
paracrine tumour-stromal interactions in HPV-negative
OPSCC models it was no surprise that these co-cultures
exhibited substantially more overall leukocyte recruitment
than HPV-positive 3D models. However, it is remarkable that
we observed significantly more neutrophil infiltration into
HPV-negative tumour-stromal models than their HPV-positive
counterparts, mirroring that observed in human patient tumour
Frontiers in Oral Health | www.frontiersin.org 11 February 2021 | Volume 2 | Article 604565
Al-Sahaf et al. Neutrophils in Oropharyngeal Cancer
samples. Treatment with anakinra significantly reduced the
recruitment of both neutrophils and monocytes into both
HPV-positive and HPV-negative tumour-stromal models,
although the treatment was far more pronounced for HPV-
negative tumour-stromal models, once again underscoring
the importance of IL-1β in immune cell recruitment to
tumours. These data are encouraging and validate the usefulness
of human 3D in vitro models to study complex tumour
microenvironment interactions with multiple cell types
that may negate some of the problems experienced in the
differences between human and murine immune systems
encountered during in vivo animal experiments and also with
2D culture.
The use of anakinra to inhibit immune cell infiltration is
an interesting concept. Indeed, anakinra was found to reduce
circulating levels of CXCL8, tumour growth and the number
of infiltrating TAM into mice bearing erlotinib-resistant
adenosquamous OSCC (Cal27) and laryngeal carcinoma
(SQ20B) xenografts grown subcutaneously. Overall survival in
these mice was increased further when they were treated with
the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor, erlotinib, indicating that this adjunct therapy may
be effective at overcoming EGFR inhibitor tumour resistance
[58]. Anakinra has also been shown to reduce the levels of
CXCL8 and number of TAM as well as reducing lymph node
metastasis in a murine model of lung cancer [59]. Whereas,
in breast cancer blocking IL-1 activity with anakinra or the
IL-1β specific antibody, canakinumab, reduced breast cancer
metastasis by inhibiting epithelial to mesenchymal transition
and preventing metastatic outgrowth of disseminated tumour
cells via inhibition of wnt signalling pathways [60–62]. Since
blockade of IL-1R by anakinra reduced leukocyte levels in both
HPV-positive and HPV-negative OPSCC in vitro, it could be
argued that this antagonist may be effective for both types of
tumour, however, the increased numbers of leukocytes recruited
to HPV-negative OPSCC suggests that the treatment would
be most effective for this cancer type. Therefore, blockade of
the IL-1/IL-1R axis may be a promising adjunct anti-tumour
therapy that would particularly affect HPV-negative OPSCC,
although there may be inherent side effects in the blocking
of this key inflammatory pathway, such as potential changes
to inflammatory signalling pathways leading to dysregulated
host inflammatory responses to infection or alterations to the
activation of important immune cells types such as natural
killer and cytotoxic T cells that are crucial in host anti-cancer
responses [63, 64].
In summary, our human in vivo and 3D tumour-stromal in
vitro data show, for the first time, that HPV-negative OPSCC
contain significantly more TAN than HPV-positive OPSCC.
Additionally, the mechanism of neutrophil recruitment appears
to be via IL-1-mediated CXCL8 release by NTF. HPV infection
appears to prevent IL-1 expression by tumour cells thereby
suppressing TAN recruitment. Since TAN have been linked with
poor prognosis, their apparent reduced recruitment to HPV-
positive tumours may partially explain the improved outcome
imparted by HPV-infection in OPSCC. Targeting the IL-1/IL-1R
axis may be a viable consideration for the treatment of HPV-
negative OPSCC.
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